Navigating 6 Analyst Ratings For Moderna

Loading...
Loading...

In the preceding three months, 6 analysts have released ratings for Moderna MRNA, presenting a wide array of perspectives from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 3 1 1 0
Last 30D 0 1 0 0 0
1M Ago 1 0 0 0 0
2M Ago 0 1 0 0 0
3M Ago 0 1 1 1 0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $119.17, a high estimate of $163.00, and a low estimate of $86.00. This upward trend is apparent, with the current average reflecting a 19.56% increase from the previous average price target of $99.67.

Interpreting Analyst Ratings: A Closer Look

The standing of Moderna among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Hartaj Singh Oppenheimer Raises Outperform $163.00 $142.00
Michael Yee Jefferies Maintains Buy $125.00 -
Luca Issi RBC Capital Maintains Outperform $125.00 -
Yifeng Liu HSBC Raises Reduce $86.00 $75.00
Luca Issi RBC Capital Maintains Outperform $125.00 -
Bill Maughan Canaccord Genuity Raises Hold $91.00 $82.00

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Moderna. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moderna compared to the broader market.
  • Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Moderna's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Moderna's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Moderna analyst ratings.

Unveiling the Story Behind Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Financial Insights: Moderna

Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.

Revenue Growth: Moderna's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -45.37%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Moderna's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 7.71%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Moderna's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.59%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Moderna's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.15%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Moderna's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.

How Are Analyst Ratings Determined?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...